Poisons Standard Amendment No. 2 of 2011

Overview

The Therapeutic Goods Act 1989 was enacted to establish a comprehensive regulatory framework for the quality, safety, efficacy, and timely availability of therapeutic goods used or exported from Australia, overseen by the Therapeutic Goods Administration. This Act also creates a unified system for controlling the availability and accessibility of poisons, ensuring their safe handling across Australia. The Act facilitates the scheduling of substances into various schedules, which imposes restrictions on their supply to safeguard public health and safety. The Therapeutic Goods Administration is responsible for administering the Act, with the Poisons Standard serving as a critical regulatory document that classifies substances into different schedules based on the recommended level of control over their public availability. The Poisons Standard Amendment No. 2 of 2011, issued under the authority of the Therapeutic Goods Act 1989, addresses the need to update the Poisons Standard to include newly identified synthetic cannabinoids in Schedule 9, reflecting their potential to cause significant harm. This amendment, made by a delegate of the Secretary to the Department of Health and Ageing, was deemed urgent and necessary to protect public health without the need for referral to expert advisory committees. The amendment process adheres to statutory procedures outlined in the Act, ensuring that the scheduling of these substances is both timely and responsive to emerging health risks.

Scope and Application

The Therapeutic Goods Act 1989 (TG Act) governs the regulation of therapeutic goods used or exported from Australia, focusing on quality, safety, efficacy, and timely availability. The Act mandates a uniform approach across states and territories to control the availability, accessibility, and safe handling of poisons. Administered by the Therapeutic Goods Administration (TGA), the Act includes provisions for the Secretary to the Department of Health and Ageing, or their delegate, to amend the Poisons Standard, which classifies substances into schedules indicating the level of control required. This amendment process can be initiated by the Secretary or on their own initiative. The Act establishes expert advisory committees to provide recommendations on scheduling matters. The Poisons Standard is pivotal in state and territory regulations and is referenced by the Commonwealth for regulatory enforcement under the TG Act. The Act prohibits advertising certain scheduled medicines to the public. The recently enacted amendments to the Poisons Standard 2010, which introduce synthetic cannabinoids into Schedule 9, were made as an urgent measure to protect public health, without referral to an expert advisory committee due to the immediacy of the risk these substances pose. These amendments, considered under the statutory procedures of the TG Act and Therapeutic Goods Regulations 1990, are not subject to disallowance under the Legislative Instruments Act 2003.

Key Provisions

The Therapeutic Goods Act 1989 (the TG Act) establishes a comprehensive regulatory framework for therapeutic goods in Australia, with specific emphasis on the safety, efficacy, and timely availability of these goods. Under section 52D(2) of the TG Act, the Secretary to the Department of Health and Ageing, or a delegate of the Secretary, has the authority to amend the Poisons Standard, which is the current document governing the scheduling of medicines and poisons. This amendment power replaces the previous authority held by the National Drugs and Poisons Schedule Committee (NDPSC), which ceased to exist following amendments to the TG Act that came into effect on 1 July 2010. The Poisons Standard consists of schedules that classify substances into nine categories, ranging from unscheduled to highly controlled substances, based on their potential for harm and the level of control necessary to protect public health. The obligations imposed by the TG Act on the parties it governs include ensuring that the supply and use of therapeutic goods adhere to the standards set forth in the Poisons Standard. This means that entities involved in the manufacture, distribution, and sale of therapeutic goods must comply with the regulations regarding the scheduling and classification of substances. For example, the advertising of prescription medicines included in Schedules 4 or 8, as well as over-the-counter medicines in Schedule 3 that are not listed in Appendix H, is prohibited. Additionally, substances in Schedule 9 or Appendix C of the Poisons Standard cannot be advertised to consumers. The TG Act also requires that the Secretary, or a delegate, consult with relevant experts when making decisions about the scheduling of substances, ensuring that these decisions are informed by the latest scientific evidence and expert opinion. Failure to comply with the provisions of the TG Act and the associated regulations can result in both civil and criminal consequences. For instance, advertising prescription medicines or over-the-counter medicines in violation of the Poisons Standard can lead to civil penalties, including fines. In more severe cases, such as the unauthorised supply of scheduled substances or the advertisement of substances in Schedule 9 or Appendix C, the penalties can include substantial fines and, in some cases, imprisonment. The specific penalties depend on the nature and severity of the offence, with maximum penalties outlined in the Therapeutic Goods Regulations 1990 (the Regulations). The legislative framework is designed to deter non-compliance and to protect the public from the potential harm associated with the misuse or abuse of scheduled substances.